# Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05784688/  
OnCo record `nct05784688` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma and colorectal cancer, run by TiumBio Co., Ltd., now recruiting.

## Summary

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05784688 by TiumBio Co., Ltd., with 140 participants planned, started 2023-03-10 and due to reach its primary completion in 2026-12. Interventions recorded: TU2218 + KEYTRUDA® (Pembrolizumab). Conditions listed: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05784688
- Phase: 1/2
- Setting: A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Sponsor: TiumBio Co., Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT05784688: https://clinicaltrials.gov/study/NCT05784688

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [TiumBio](https://onco.cc/companies/tiumbio/)

---
JSON: https://onco.cc/api/v1/entities/nct05784688.json